Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SK potassium channel inhibitors - Acesion Pharma

Drug Profile

Research programme: SK potassium channel inhibitors - Acesion Pharma

Alternative Names: AP14145; NS 309; NS 4591; NS 8593

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroSearch
  • Developer Acesion Pharma; NeuroSearch
  • Class Indoles; Oximes; Small molecules
  • Mechanism of Action Intermediate conductance calcium activated potassium channel modulators; Small conductance calcium activated potassium channel modulators; Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Atrial fibrillation
  • Discontinued Chronic obstructive pulmonary disease; Epilepsy; Overactive bladder

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Atrial-fibrillation in Denmark
  • 08 Feb 2018 Acesion Pharma plans a phase I trial of AP 30663 for Atrial fibrillation (In healthy volunteers) in Netherlands in March 2018
  • 26 Aug 2017 Pharmacodynamics data from a preclinical trial in Atrial fibrillation presented at the Annual Congress of the European Society of Cardiology (ESC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top